Accelerate Registration of Medical Products
Efforts in research and development of medical products for diseases disproportionately affecting people in low and lower middle-income countries have been multiplied. Yet, after successful development of a medical product 4-7 years elapse before it is registered in these countries. Through the World Health Organisation and the Swiss Agency for Therapeutic Products, SDC aims to strengthen capacities of African medicines regulatory authorities and increase the efficiency of regional and global medicines regulatory procedures.
Renforcement des systèmes de santé
- Around 80 guidelines were developed and endorsed at national level by the respective EAC Members States.
- Five generic (non-patented) products, previously approved through the WHO prequalification programme, were registered within one to three months in all five EAC Member States thanks to joint dossier assessments.
- Organisation mondiale de la santé
Access to safe and efficacious quality medical products is a complex issue. A major factor delaying access that is often overlooked is the lengthy evaluation and registration procedure that may last up to 7 years in some low and lower-middle income countries. This “drug-lag” causes unnecessary ill-health and death.
Foster access to efficacious and safe quality medical products for people in low and middle-income countries, especially in sub-Saharan Africa, through medicines regulatory systems strengthening at the global, regional and country level.
Primary beneficiaries are people in East African and other low and lower middle-income countries who are in need of medical products for which marketing authorisation at the level of Swissmedic and registration in their home countries will be sought. Secondary beneficiaries are collaborators of the six national medicines regulatory authorities in the East African Community who benefit from capacity building measures provided by WHO and Swissmedic in the countries. Organisations that seek marketing authorisation for their global health products are also beneficiaries.
|Effets à moyen terme||
Evaluation and registration of medical products for diseases disproportionately affecting people in low and lower middle-income countries is accelerated at the global and national level.
Principaux résultats attendus:
Output 1: The technical and managerial capacities of national medicines regulatory authorities (NMRAs) in Member States in the East African Community (EAC) are strengthened.
Output 2: Regional harmonization: Medical product dossiers submitted to the EAC NMRAs are jointly assessed in accordance with harmonised guidelines and established procedures.
Output 3: Swissmedic marketing authorisation procedure for medical products against diseases disproportionately affecting people in low and lower middle-income countries is used by relevant applicants (e.g. Product Development Partnerships).
Output 4: Swissmedic scientific advice procedure during developmental phase of a medical product for diseases disproportionately affecting people in low and lower middle-income countries is used by NMRAs and the WHO pre-qualification programme.
Principaux résultats antérieurs:
|Direction/office fédéral responsable||
Coopération au développement
|Partenaire de projet||
Organisme des Nations Unies (ONU)
Swiss Agency for Therapeutic Products (Swissmedic), Bill and Melinda Gates Foundation, East African Community, Agency for New Partnership for Africa’s Development
|Coordination avec d'autres projets et acteurs||
Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), Swiss Tropical and Public Health Institute (Swiss TPH)
|Budget||Phase en cours Budget de la Suisse CHF 1'970'000 Budget suisse déjà attribué CHF 1'970'000|
|Phases du projet||
(Phase en cours)
Phase 1 01.12.2015 - 31.12.2018 (Completed)